Skip to main content
OpenTrials
Completed

NCT Number: NCT07509905

TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nausea Post Chemotherapy Acupuncture Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive Transcutaneous Electrical Acupoint Stimulation Vomiting

Age range

40 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Cancer Institute in Damietta.

Damietta, Egypt

About this study

Chemotherapy-induced nausea and vomiting significantly impacts the quality of life for 70%-80% of cancer patients receiving chemotherapy. The P6 acupressure point is traditionally used to relieve these symptoms and has shown benefits in pain relief and other conditions. If studies on Transcutaneous electrical acupoint stimulation yield positive results, it could be integrated as an effective method to manage chemotherapy-induced nausea and vomiting, enhancing patient comfort and treatment outcomes while potentially reducing the need for dosage adjustments. This study aims to address gaps in current treatments, improving management and quality of life for affected cancer patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female patients who their ages between 40 and 60.
  • All patients diagnosed with cancer and planned to receive TACE treatment with cisplatin (60 mg) as the main drug. The chemotherapy regimen will not include steroids.
  • Karnofsky's score ≥60.
  • All patients will receive the same antiemetic drug.
  • None of them receiving other physical therapy modalities to treat nausea and vomiting.
  • The skin of acupoint site receiving electrical acupoint stimulation must be intact and without visible evidence of injury
  • All patient can tolerate mild discomfort following electrical stimulation.
  • All patients enrolled in the study will have their informed consent.

Exclusion criteria

  • Combined use of other venous chemotherapy within 5 days after Transarterial Chemoembolization
  • Other confounding factors that may cause nausea and vomiting (such as intestinal obstruction, anorexia, and so on)
  • Having vomited or used 5 HT3 receptor antagonists or other antiemetics within 24 hours before Transarterial Chemoembolization .
  • Receiving concurrent radiotherapy
  • Severe uncontrolled complications and unstable metastases
  • Installing pacemaker, Pregnancy.
  • History of convulsions or seizure disorder.
  • Cognitive dysfunction, unable to finish Scale
  • Transcutaneous electrical acupoint stimulation treatment within the past year regardless of indication.

Treatment and study plan

Transcutaneous electrical nerve stimulation

Device

The acupoints were wiped with a moist cotton swab and then connected to the anode and cathode of the electrical stimulation generator through an electrode patch placed on the skin surface.

Continuous wave form mode was selected, and then the electric current produced continuous stimulation on the acupoints. Stimulation frequency was set at 4 Hz, and the default value was set as 10 mA, which was twice the sensory threshold (5 mA). The intensity was adjusted every 10 min to keep the patients comfortable, and its actual value ranged from 7 to 15 mA.

Antiemetic

Drug

the drug is being taken once a day for 72 hours after introducing chemotherapy

Primary outcomes

  1. Assessment of nausea

    Time frame: At the day of chemotherapy administration and the following 5 days

    The M. D. Anderson Symptom Inventory MD Anderson Symptom Inventory is a multi-symptom patient-reported outcome measure for clinical and research use. The MD Anderson Symptom Inventory 's thirteen core items include symptoms found to have the highest frequency and/or severity in patients with various cancers and treatment types. Each symptom is being scored between 0 and 10, were 0 means no effect and 10 means greatest severity.

Secondary outcomes

  1. Assessment of vomiting

    Time frame: At the day of chemotherapy administration and the following 5 days

    Visual analog scale for anorexia is a widely used tool for assessing subjective symptoms, including anorexia. It consists of a horizontal or vertical line, typically 100 mm long, where patients mark their perceived intensity of a symptom-ranging from "no anorexia" to "worst possible anorexia"

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 3, 2026
Registry last updated
Apr 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.